50.04
-0.06%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CRISPR Therapeutics
From its filings with the US Securities and Exchange Commission
CRISPR Therapeutics is based in Zug and is incorporated in Switzerland. Its shares trade on Nasdaq under the ticker CRSP. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $3.5m and a net loss of $581.6m. At that date it held total assets of $2.27bn and shareholders' equity of $1.92bn.
Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex.
We have established a portfolio of therapeutic programs spanning four core franchises: hemoglobinopathies, in vivo, CAR T approaches and regenerative medicine. Depending on the program, we take either an ex vivo approach, in which we edit cells outside of the human body before administering them to the patient, or an in vivo editing approach, where we deliver the CRISPR-based therapeutic directly to target cells within the human body.
We continue to innovate on our platform to develop next-generation technologies that can enable new therapies. We are developing other technologies, including delivery technologies and other gene editing technologies, like SyNTase. Through our efforts, we aim to unlock the full potential of gene-based therapeutics to create medicines that can transform people’s lives.
Quoted from its 10-K, filed 12 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Employees
- 63
- Website
- crisprtx.com/about-us/contact ↗
- Head office
- BAARERSTRASSE 14, ZUG
- Incorporated in
- V8
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Samarth KulkarniChairman of the Board, Chief Executive Officer, since 2017$33.2m
- Dr. Raju PrasadChief Financial Officer$5.5m
- Mr. James KasingerGeneral Counsel, Secretary$6.1m
- Dr. Naimish PatelChief Medical Officer$6.4m
- Dr. Douglas TrecoLead Independent Director$500,847
- Dr. Ali BehbahaniIndependent Director$470,106
- Dr. Maria FardisIndependent Director$467,606
- Dr. H. Edward FlemingIndependent Director$465,106
- Dr. Simeon GeorgeIndependent Director$472,606
- Mr. John GreeneIndependent Director$485,106
- Dr. Katherine HighIndependent Director$462,606
- Mr. Sandesh MahatmeIndependent Director$461,383
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 58
- Environment
- 34
- Social
- 95
- Governance
- 44
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong Intellectual Property: CRISPR Therapeutics AG possesses a robust portfolio of patents related to CRISPR gene-editing technology, providing them with a competitive advantage in the market.
- Cutting-Edge Technology: The company specializes in developing innovative gene therapies utilizing CRISPR-Cas9, a revolutionary genome editing technique with immense potential for treating genetic diseases.
- Strategic Partnerships: CRISPR Therapeutics AG has established collaborations with leading pharmaceutical companies, which strengthens their research capabilities, expands their reach, and facilitates licensing opportunities.
Weaknesses
- Limited Clinical Pipeline: Although CRISPR Therapeutics AG has several promising programs in preclinical and early clinical stages, their current pipeline of potential therapies is relatively small compared to some competitors.
- Regulatory Challenges: As with any novel therapeutic approach, CRISPR gene editing faces regulatory hurdles and ethical concerns, which may delay approval processes and affect market adoption.
Opportunities
- Unmet Medical Needs: The increasing prevalence of genetic disorders combined with limited treatment options presents a significant opportunity for CRISPR Therapeutics AG to address unmet medical needs and create breakthrough therapies.
- Expansion into New Indications: CRISPR gene editing has the potential to be applied beyond genetic diseases, such as cancer immunotherapies or agricultural advancements. CRISPR Therapeutics AG can explore these new indications to diversify their product portfolio.
Threats
- Competition: CRISPR Therapeutics AG operates in a highly competitive landscape with other biotechnology companies also exploring gene-editing technologies. Increased competition may affect market share and limit pricing power.
- Intellectual Property Disputes: There is ongoing litigation and disputes surrounding the intellectual property rights related to CRISPR-Cas9 technology, which may impact the exclusivity and commercialization opportunities for CRISPR Therapeutics AG.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.